Effects of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 on HCC
MM Kirstein, AE Boukouris, D Pothiraju, LE Buitrago-Molina, S Marhenke, J Orlik, MP Manns, A Vogel · Zeitschrift für Gastroenterologie · 2013 · Heft 01
Bibliografische Angaben
Zusammenfassung
Introduction: Hepatocellular carcinoma (HCC) is one of the most deadly cancers worldwide with only few therapeutic options for patients with advanced disease. Aberrant mTOR signaling has been identified in up to 50–60% of cases of hepatocellular carcinoma and therefore represents a promising target for novel therapeutic approaches. This study evaluated the anti-tumor effect of the mTOR inhibitor RAD001, the dual PI3-kinase and mTOR inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in human hepatoma cell lines in vitro and in a HCC xenograft mouse model. Experimental Design: The anti-tumor effects of RAD001, B…
